Pipeline

OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED).

A Focus on Ocular Therapies

Pipeline

OK-101

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3

Dry Eye Disease (DED)

Phase 2 trial completed

Phase 2 trial completedPhase 2

Neuropathic Corneal Pain (NCP)

Plan to open trial in Q3 2024

Plan to open trial in Q3 2024Phase 1

Allergic Conjunctivitis

Preclinical

Uveitis

Preclinical

OK-201

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3

Discovery Program

OK-101 Development Timeline

  • Skipping Phase 1
  • Designing Phase 2 effectively as a Phase 3 registration trial